Gastroenterol Res

Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access

Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc

Journal website http://www.gastrores.org

Original Article

Volume 8, Number 2, April 2015, pages 171-177

Gastroduodenal Changes Two Years After Eradication of Helicobacter pylori in a Population-Based Cohort

**Table 1.** Background Variables
	Female	Male	Total
N	35	47	82
Follow-up time after eradication	-	-	29.8 months (23.6 - 145.2)
Follow-up time, person years			269.6
Median age at eradication treatment (range)	70.0 (41.0 - 81.8)	66.5 (51.3 - 86.8)	68.9 (41.0 - 86.8)
History of ulcer in total			17 (baseline 9, first follow-up 3, present study 5)

Table 1. Background Variables

Female

Male

Total

Follow-up time after eradication

29.8 months (23.6 - 145.2)

Follow-up time, person years

269.6

Median age at eradication treatment (range)

70.0 (41.0 - 81.8)

66.5 (51.3 - 86.8)

68.9 (41.0 - 86.8)

History of ulcer in total

17 (baseline 9, first follow-up 3, present study 5)

**Table 2.** Hormonal Changes Observed at Baseline and at Follow-Up After *H. pylori* Eradication
N = 82	Baseline	Follow-up	P
Chronic gastritis at histology and at least one positive H. pylori test before eradication of H. pylori, McNemar.
NSAID use: at least weekly, including low dose	19/59	5/10	0.007
Post Hp-serology	0	68	0.001
PGI/PGII < 3.0	0	3	0.001
P-gastrin > 50	1	6	0.625
Urea breath test > 2.5	0	1	< 0.0001
P-CCK, median (range)	0.7 (0.1 - 2.5)	0.1 (0.1 - 1.9)	< 0.0001
P-gastrin, median (range)	9.0 (1.0 - 214)	6.0 (3.0 - 1,242)	< 0.0001
P-somatostatin, median (range)	6.0 (0.0 - 32.0)	13.0 (0.0 - 36.0)	< 0.0001

Table 2. Hormonal Changes Observed at Baseline and at Follow-Up After H. pylori Eradication

N = 82

Baseline

Follow-up

Chronic gastritis at histology and at least one positive H. pylori test before eradication of H. pylori, McNemar.

NSAID use: at least weekly, including low dose

19/59

5/10

0.007

Post Hp-serology

0.001

PGI/PGII < 3.0

0.001

P-gastrin > 50

0.625

Urea breath test > 2.5

< 0.0001

P-CCK, median (range)

0.7 (0.1 - 2.5)

0.1 (0.1 - 1.9)

< 0.0001

P-gastrin, median (range)

9.0 (1.0 - 214)

6.0 (3.0 - 1,242)

< 0.0001

P-somatostatin, median (range)

6.0 (0.0 - 32.0)

13.0 (0.0 - 36.0)

< 0.0001

**Table 3.** Abdominal Symptoms at Baseline and Follow-Up
	Baseline, yes/no	Follow-up, yes/no	P, Wilcoxon
In the study population in frequency of never, not every month, every month, but not every week, every week, but not every day, every day and here in total. Symptoms that last 3 months.
Abdominal pain total	24/68	16/68	0.116 NS
Epigastric pain	7/68	2/68	0.028
Lower abdominal pain	15/64	12/64	0.503 NS
Acid regurgitation	45/72	43/72	0.549 NS
Acid reflux	40/72	39/72	0.839 NS
Dysphagia	8/72	10/72	0.782 NS
Nausea	24/72	28/72	0.698 NS
Vomiting	11/72	11/92	> 0.999 NS
Bloating after meal	35/71	38/71	0.322 NS
Bloating general	27/71	38/71	0.723 NS
Gas	53/72	60/72	0.111 NS
Constipation	40/70	41/70	0.838 NS
Diarrhea	41/71	40/71	0.860 NS

Table 3. Abdominal Symptoms at Baseline and Follow-Up

Baseline, yes/no

Follow-up, yes/no

P, Wilcoxon

In the study population in frequency of never, not every month, every month, but not every week, every week, but not every day, every day and here in total. Symptoms that last 3 months.

Abdominal pain total

24/68

16/68

0.116 NS

Epigastric pain

7/68

2/68

0.028

Lower abdominal pain

15/64

12/64

0.503 NS

Acid regurgitation

45/72

43/72

0.549 NS

Acid reflux

40/72

39/72

0.839 NS

Dysphagia

8/72

10/72

0.782 NS

Nausea

24/72

28/72

0.698 NS

Vomiting

11/72

11/92

> 0.999 NS

Bloating after meal

35/71

38/71

0.322 NS

Bloating general

27/71

38/71

0.723 NS

Gas

53/72

60/72

0.111 NS

Constipation

40/70

41/70

0.838 NS

Diarrhea

41/71

40/71

0.860 NS

**Table 4.** Morphology
N = 82	Antrum 2, 0-3/N	Antrum 3, 0-3/N	P	Corpus 2, 0-3/N	Corpus 3, 0-3/N	P
Antrum and corpus at first (2) and second (3) follow-up. These morphological features are semi-quantitatively assessed on a four-graded scale (visual analogue scale) equivalent to verbal description none = 0, mild = 1, moderate = 2 and severe = 3. In total 82 persons were investigated; it was not enough material for analysis at all locations.
Chronic inflammation	0/2 1/38 2/42 3/0	0/60 1/22 2/0 3/0	< 0.0001	0/3 1/54 2/22 3/3	0/58 1/23 2/1 3/0	< 0.0001
Atrophy	0/60 1/18 2/1 3/2	0/72 1/8 2/0 3/1	0.003	0/64 1/10 2/7 3/1	0/74 1/5 2/1 3/2	0.014
Inflammatory activity	0/12 1/56 2/14 3/0	0/79 1/3 2/0 3/0	< 0.0001	0/24 1/47 2/10 3/1	0/80 1/1 2/1 3/0	< 0.0001
Intestinal metaplasia	0/58 1/21 2/1 3/2	0/64 1/15 2/2 3/1	0.142	0/74 1/5 2/3 3/0	0/72 1/9 2/0 3/1	0.734

Table 4. Morphology

N = 82

Antrum 2, 0-3/N

Antrum 3, 0-3/N

Corpus 2, 0-3/N

Corpus 3, 0-3/N

Antrum and corpus at first (2) and second (3) follow-up. These morphological features are semi-quantitatively assessed on a four-graded scale (visual analogue scale) equivalent to verbal description none = 0, mild = 1, moderate = 2 and severe = 3. In total 82 persons were investigated; it was not enough material for analysis at all locations.

Chronic inflammation

0/2
1/38
2/42
3/0

0/60
1/22
2/0
3/0

< 0.0001

0/3
1/54
2/22
3/3

0/58
1/23
2/1
3/0

< 0.0001

Atrophy

0/60
1/18
2/1
3/2

0/72
1/8
2/0
3/1

0.003

0/64
1/10
2/7
3/1

0/74
1/5
2/1
3/2

0.014

Inflammatory activity

0/12
1/56
2/14
3/0

0/79
1/3
2/0
3/0

< 0.0001

0/24
1/47
2/10
3/1

0/80
1/1
2/1
3/0

< 0.0001

Intestinal metaplasia

0/58
1/21
2/1
3/2

0/64
1/15
2/2
3/1

0.142

0/74
1/5
2/3
3/0

0/72
1/9
2/0
3/1

0.734

**Table 5.** Duodenal Inflammation and Gastric Metaplasia at First (2) and Second (3) Follow-Up
N = 77	B 2, 0-3	B 3, 0-3	P, McNemar
The visual analogue scale 0 - 4 was used.
Bulbitis	0/66, 1/6, 2/4, 3/1	0/74, 1/3, 2/0, 3/0	0.013
Gastric metaplasia	0/53, 1/25, 2/4, 3/0	0/46, 1/25, 2/6, 3/0	0.171

Table 5. Duodenal Inflammation and Gastric Metaplasia at First (2) and Second (3) Follow-Up

N = 77

B 2, 0-3

B 3, 0-3

P, McNemar

The visual analogue scale 0 - 4 was used.

Bulbitis

0/66, 1/6, 2/4, 3/1

0/74, 1/3, 2/0, 3/0

0.013

Gastric metaplasia

0/53, 1/25, 2/4, 3/0

0/46, 1/25, 2/6, 3/0

0.171